A three-dimensional pharmacophore model for IMPDH inhibitors

Chemical Biology and Drug Design

Volumn 78, Issue 1, 2011, Pages 175-182

  Yang, Na ^a   Wang, Jian ^a   Li, Jian ^a   Wang, Qing He ^a   Wang, Yu ^a   Cheng, Mao Sheng ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

HypoRefine hypothes; Inosine 5' monophosphate dehydrogenase inhibitors; Molecular docking; Pharmacophore model

Indexed keywords

INOSINATE DEHYDROGENASE INHIBITOR;

ARTICLE; DRUG ACTIVITY; DRUG SYNTHESIS; HYDROGEN BOND; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL;

ENZYME INHIBITORS; IMP DEHYDROGENASE; MODELS, MOLECULAR;

EID: 79958795106     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01128.x     Document Type: Article

References (38)

1. Jackson R.C., Weber G., Morris H.P. (1975) IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature;256:331-333.
2. Hedstrom L. (1999) IMP dehydrogenase: mechanism of action and inhibition. Curr Med Chem;6:545-560.
3. Sintchak M.D., Nimmesgern E. (2000) The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology;47:163-184.
4. Collart F.R., Huberman E. (1988) Cloning and sequence analysis of the human and Chinese hamster inosine-5'-monophosphate dehydrogenase cDNAs. J Biol Chem;263:15769-15772.
5. Natsumeda Y., Ohno S., Kawasaki H., Konno Y., Weber G., Suzuki K. (1990) Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem;265:5292-5295.
6. Jain J., Almquist S.J., Ford P.J., Shlyakhter D., Wang Y., Nimmesgern E., Germann U.A. (2004) Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol;67:767-776.
7. Carr S.F., Papp E., Wu J.C., Natsumeda Y. (1993) Characterization of human type I and type II IMP dehydrogenases. J Biol Chem;268:27286-27290.
8. Jayaram H.N., Cooney D.A., Grusch M., Krupitza G. (1999) Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis. Curr Med Chem;6:561-574.
9. Gu J.J., Tolin A.K., Jain J., Huang H., Santiago L., Mitchell B.S. (2003) Targeted disruption of the inosine 5'-monophosphate dehydrogenase type I gene in mice. Mol Cell Biol;23:6702-6712.
10. Nair V., Ussery M.A. (1992) New hypoxanthine nucleosides with RNA antiviral activity. Antiviral Res;19:173-178.
11. Franchetti P., Cappellacci L., Grifantini M. (1996) IMP dehydrogenase as a target of antitumor and antiviral chemotherapy. Farmaco;51:457-469.
12. Jain J., Almquist S.J., Shlyakhter D., Harding M.W. (2001) VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci;90:625-637.
13. Jain J., Almquist S.J., Heiser A.D., Shlyakhter D., Leon E., Memmott C., Moody C.S., Nimmesgern E., Decker C. (2002) Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther;302:1272-1277.
14. Pankiewicz K.W., Patterson S.E., Black P.L., Jayaram H.N., Risal D., Goldstein B.M., Stuyver L.J., Schinazi R.F. (2004) Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH) - the major therapeutic target. Curr Med Chem;11:887-900.
15. Ratcliffe A.J. (2006) Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases. Curr Opin Drug Discov Devel;9:595-605.
16. Chen L., Pankiewicz K.W. (2007) Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel;10:403-412.
17. Nair V., Shu Q. (2007) Inosine monophosphate dehydrogenase as a probe in antiviral drug discovery. Antivir Chem Chemother;18:245-258.
18. Qingning S., Vasu N. (2008) Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery. Med Res Rev;28:219-232.
19. Dhar T.G., Liu C., Pitts W.J., Guo J., Watterson S.H., Gu H., Fleener C.A., Rouleau K., Sherbina N.Z., Barrish J.C., Hollenbaugh D., Iwanowicz E.J. (2002) A survey of cyclic replacements for the central diamide moiety of inhibitors of inosine monophosphate dehydrogenase. Bioorg Med Chem Lett;12:3125-3128.
20. Dhar T.G., Shen Z., Fleener C.A., Rouleau K.A., Barrish J.C., Hollenbaugh D.L., Iwanowicz E.J. (2002) The TosMIC approach to 3-(oxazol-5-yl) indoles: application to the synthesis of indole-based IMPDH inhibitors. Bioorg Med Chem Lett;12:3305-3308.
21. Dhar T.G., Shen Z., Guo J., Liu C., Watterson S.H., Gu H.H., Pitts W.J. (2002) Discovery of N-[2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity. Bioorg Med Chem Lett;45:2127-2130.
22. Gu H.H., Iwanowicz E.J., Guo J., Watterson S.H., Shen Z., Pitts W.J., Dhar T.G.M., Fleener C.A., Rouleau K., Sherbina N.Z., Witmer M., Tredup J., Hollenbaugh D. (2002) Novel diamide-based inhibitors of IMPDH. Bioorg Med Chem Lett;12:1323-1326.
23. Iwanowicz E.J., Watterson S.H., Liu C., Gu H.H., Mitt T., Leftheris K., Barrish J.C., Fleener C.A., Rouleau K., Sherbina N.Z., Hollenbaugh D.L. (2002) Novel guanidine-based inhibitors of inosine monophosphate dehydrogenase. Bioorg Med Chem Lett;12:2931-2934.
24. Pitts W.J., Guo J., Dhar T.G., Shen Z., Gu H.H., Watterson S.H., Bednarz M.S., Chen B., Barrish J.C., Bassolino D., Cheney D., Fleener C.A., Rouleau K.A., Hollenbaugh D.L., Iwanowicz E.J. (2002) Rapid synthesis of triazine inhibitors of inosine monophosphate dehydrogenase. Bioorg Med Chem Lett;12:2137-2140.
25. Watterson S.H., Liu C., Dhar T.G., Gu H.H., Pitts W.J., Barrish J.C., Fleener C.A., Rouleau K., Sherbina N.Z., Hollenbaugh D.L., Iwanowicz E.J. (2002) Novel amide-based inhibitors of inosine 5'-monophosphate dehydrogenase. Bioorg Med Chem Lett;12:2879-2882.
26. Chen P., Norris D., Haslow K.D., Murali Dhar T.G., Pitts W.J., Watterson S.H., Cheney D.L., Bassolino D.A., Fleener C.A., Rouleau K.A., Hollenbaugh D.L., Townsend R.M., Barrish J.C., Iwanowicz E.J. (2003) Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors. Bioorg Med Chem Lett;13:1345-1348.
27. Dhar T.G., Shen Z., Gu H.H., Chen P., Norris D., Watterson S.H., Ballentine S.K., Fleener C.A., Rouleau K.A., Barrish J.C., Townsend R., Hollenbaugh D.L., Iwanowicz E.J. (2003) 3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett;13:3557-3560.
28. Dhar T.G., Watterson S.H., Chen P., Shen Z., Gu H.H., Norris D., Carlsen M. et al. (2003) Quinolone-based IMPDH inhibitors: introduction of basic residues on ring D and SAR of the corresponding mono, di and benzofused analogues. Bioorg Med Chem Lett;13:547-551.
29. Iwanowicz E.J., Watterson S.H., Guo J., Pitts W.J., Murali Dhar T.G., Shen Z., Chen P., Gu H.H., Fleener C.A., Rouleau K.A., Cheney D.L., Townsend R.M., Hollenbaugh D.L. (2003) Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety. Bioorg Med Chem Lett;13:2059-2063.
30. Pickett S.D., Sherborne B.S., Wilkinson T., Bennett J., Borkakoti N., Broadhurst M., Hurst D., Kilford I., McKinnell M., Jones P.S. (2003) Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorg Med Chem Lett;13:1691-1694.
31. Watterson S.H., Carlsen M., Dhar T.G., Shen Z., Pitts W.J., Guo J., Gu H.H. et al. (2003) Novel inhibitors of IMPDH: a highly potent and selective quinolone-based series. Bioorg Med Chem Lett;13:543-546.
32. Watterson S.H., Dhar T.G., Ballentine S.K., Shen Z., Barrish J.C., Cheney D., Fleener C.A., Rouleau K.A., Townsend R., Hollenbaugh D.L., Iwanowicz E.J. (2003) Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3. Bioorg Med Chem Lett;13:1273-1276.
33. Birch H.L., Buckley G.M., Davies N., Dyke H.J., Frost E.J., Gilbert P.J., Hannah D.R. et al. (2005) Novel 7-methoxy-6-oxazol-5-yl-2, 3-dihydro-1H-quinazolin-4-ones as IMPDH inhibitors. Bioorg Med Chem Lett;15:5335-5339.
34. Buckley G.M., Davies N., Dyke H.J., Gilbert P.J., Hannah D.R., Haughan A.F., Hunt C.A., Pitt W.R., Profit R.H., Ray N.C., Richard M.D., Sharpe A., Taylor A.J., Whitworth J.M., Williams S.C. (2005) Quinazolinethiones and quinazolinediones, novel inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett;15:751-754.
35. Beevers R.E., Buckley G.M., Davies N., Fraser J.L., Galvin F.C., Hannah D.R., Haughan A.F., Jenkins K., Mack S.R., Pitt W.R., Ratcliffe A.J., Richard M.D., Sabin V., Sharpe A., Williams S.C. (2006) Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett;16:2539-2542.
36. Beevers R.E., Buckley G.M., Davies N., Fraser J.L., Galvin F.C., Hannah D.R., Haughan A.F., Jenkins K., Mack S.R., Pitt W.R., Ratcliffe A.J., Richard M.D., Sabin V., Sharpe A., Williams S.C. (2006) Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett;16:2535-2538.
37. Watterson S.H., Chen P., Zhao Y., Gu H.H., Dhar T.G., Xiao Z., Ballentine S.K. (2007) Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1-yl)pyridin-3-yl)propan-2-yl)-2- fluoro-9-oxo-9, 10-dihydroacridine-3-carboxamide (BMS-566419). J Med Chem;50:3730-3742.
38. Smellie A., Teig S.L., Towbin P. (1995) Poling: promoting conformational variation. J Comput Chem;16:171-187.